ArticlePsoriasis (Auckland, N.Z.)2025
Global Trends and Future Predictions of Psoriasis Burden: Insights from the GBD 2021 Study.
Article in Psoriasis (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inequality and determinants of access to phototherapy among patients with psoriasis in Thailand.Skin health and disease · 2026Article
- Seasonal Variation of Plaque Psoriasis in Relation to Individualized MED-Adjusted Ultraviolet Exposure: A Cross-Sectional Study in Poland.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is a common chronic inflammatory skin disorder, and the global burden of psoriasis has not been fully disclosed. Methods: We extracted prevalence, incidence and disability-adjusted life years (DALYs) for psoriasis from 1990 to 2021 in Global Burden of Disease (GBD) and predicted trends in the next 15 years though ARIMA model. Results: Globally, age-standardized incidence rate (ASIR) of psoriasis increased from 57 cases/100,000 people (95% CI: 55.3~58.8) in 1990 to 62 cases/100,000 people (95% CI: 60.1~63.9) in 2021. Age-standardized prevalence rate (ASPR) and age-standardized disability-adjusted life year rate (ASDR) exhibited similar trends of increases. The global ASIR, ASPR, and ASDR for males were significantly higher than females. In 2021, ASIR peaked in the 55-69 ages, while ASPR and ASDR reached peaks between the ages of 65-74. Regionally, ASPR, ASIR, and ASDR in 2021 were highest in high Socio-demographic index (SDI) regions. The highest global regions and countries of ASPR, ASIR and ASDR were Western Europe and Germany, respectively. The East Asia region and Republic of Equatorial Guinea showed most significant growth in these psoriasis indicators since 1990. Furthermore, there was a significant increase in ASIR (8.06%), ASPR (8.14%), and ASDR (13.64%) of global psoriasis over the next 15 years. Conclusions: Global burden of psoriasis is expected to continuously increase, and strengthening risk-factor management and prioritizing high-risk subgroups (males, elderly, high SDI regions and Western Europe, etc) will be essential for region-specific strategies and future healthcare planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.